2021-01-15
Kancera appoints a Scientific Advisory Board with leading scientists in cardiology and immunology
This is a translation of a press release in Swedish published December 21, 2020
Read More
2020-12-02
Agreement on development of HDAC6 inhibitors discontinued.
Kancera AB announces today that the pharmaceutical company Grünenthal GmbH has chosen to terminate the parties' research and option agreement. Since the end of 2018, Grünenthal has been responsible for the development of Kancera's series of HDAC6 inhibitors and...
Read More
2020-11-20
Interim report for the third quarter 2020, January 1st – September 30th, 2020
Third quarter in brief as well as the period 1 January – 30 September 2020 Net sales for the period (January to September) amounted to SEK 0,09 million (3,3 million), of which the third quarter contributed SEK 0,05 million...
Read More
2020-10-01
Kancera starts study in covid-19 patients
Kancera AB (Nasdaq First North Premier Growth Market: KAN) announces that screening of covid-19 patients for the clinical phase II study of KAND567 starts today. The study, which is carried out in collaboration with Capio St. Göran’s Hospital and...
Read More
2020-08-21
Interim report for the second quarter 2020. January 1st – June 30th, 2020
Second quarter in brief and the period 1 January – 30 June 2020 Net sales for the period (January to June) amounted to SEK 2,6 million (3,1 million), of which the second quarter contributed SEK 2,6 million (0)....
Read More
2020-07-10
Fraktalkine pathway mechanism of action for Kancera drug candidate KAND567 is linked to reduced risk of serious complications in COVID-19
Preparation for a clinical study with KAND567 in COVID-19 patients now under way Kancera AB (Nasdaq First North Premier Growth Market: KAN) today announces that independent researchers have published results showing that the fraktalkine system is activated in Covid-19 patients and that...
Read More
2020-06-15
Kancera’s drug candidate KAND567 has a positive effect on mobility in a preclinical model of spinal cord injury
Kancera AB (Nasdaq First North Premier Growth Market: KAN) announces that an independent research group has published results showing that the company's drug candidate KAND567 has a protective effect on nerve tissue and its function in a preclinical disease model of spinal...
Read More
2020-06-10
Interim report for the first quarter 2020, 1 januari-31 March 2020 Kancera AB (publ.), org.nr. 556806-8851.
First quarter in brief 1 January – 31 March 2020 Net sales for the period (January to March) amounted to SEK 0,04 million (3,1). R&D costs for the period amounted to SEK 9,7 million (10,2). Operating profit for the...
Read More
2020-05-14
Kancera applies for a Phase II study with KAND567 in covid-19 patients
This is a translation of a press release in Swedish dated 2020-05-13 Kancera today announces that the company has submitted an application to the Swedish Medicines Agency for permission to conduct a phase II clinical study of the drug candidate KAND567 in...
Read More
2020-03-06
Kancera provides an update on the development of the drug candidate KAND145
Kancera AB (Nasdaq First North Premier Growth Market: KAN) today provides an update on the development of the drug candidate KAND145. Results from the ongoing patenting process underscores the level of innovation of KAND145. In addition, positive clinical results from the Phase...
Read More